menu

Cardiovascular Risk Reduction in Type 2 Diabetes & ASCVD: An Interventional Cardiologist’s Perspective

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Cardiovascular Risk Reduction in Type 2 Diabetes & ASCVD: An Interventional Cardiologist’s Perspective

Program Information
Recommended

Program Information

ReachMD Healthcare Image
RestartResume

Explore the latest evidence-based recommendations toward reducing the serious cardiovascular risks many patients with type 2 diabetes face. 

  • Sponsored by

  • Overview

    Type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) can have detrimental impacts on our patients. In fact, it’s been shown that life expectancy for patients with both type 2 diabetes and ASCVD (stroke and heart attack) may be nearly 15 years shorter than those without diabetes.1,2 So how can we reduce the risk of major adverse cardiovascular events for these patients? Joining Dr. Jennifer Caudle to share his perspective as an interventional cardiologist is Dr. Robert Chilton, Professor of Medicine and Director of the Cardiac Catheterization Laboratory at the University of Texas Health Science Center at San Antonio.

    Reference:
    1. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation. 2016;133(24):2459-2502.
    2. Emerging Risk Factors Collaboration, Di Angelantonio E, Kaptoge S, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314(1):52-60.

    Novo Nordisk is a registered trademark of Novo Nordisk A/S.
    © 2022 Novo Nordisk All rights reserved.
    US22DI00239 September 2022

Schedule3 Feb 2023